Format

Send to

Choose Destination
J Cancer Res Ther. 2009 Sep;5 Suppl 1:S16-20. doi: 10.4103/0973-1482.55135.

Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors.

Author information

1
Division of Radiation Biosciences, Institute of Nuclear Medicine and Allied Sciences, New Delhi, India.

Abstract

The development of an approach based on the energy-linked modification of DNA repair and cellular recovery processes using 2-deoxy-D-glucose (2-DG; inhibitor of glycolytic ATP production) has shown promising results in a number of model systems of cancer. Following encouraging results on the tolerance and toxicity (acute as well as late effects) of the combination (2-DG and hypofractionated radiotherapy) in Phase I and II clinical trials, its efficacy is currently under evaluation in Phase III clinical trials for glioma patients. Since heterogeneous physiologic and metabolic status in tumors as well as host-tumor interactions influence the local tumor control, which coupled with systemic disturbances could determine the cure (long-term tumor free survival), investigations on the in vivo responses of tumors to the combined treatment have received considerable attention. This communication provides a brief overview on the in vivo studies related to radio- and chemosensitization of tumors by 2-DG, besides the normal tissue toxicity induced by the combined treatment of 2-DG and radiation or chemotherapeutic drugs.

PMID:
20009287
DOI:
10.4103/0973-1482.55135
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center